Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Boehringer Ingelheim
Merck
Moodys
Harvard Business School

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Litigation Details for Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

See Plans and Pricing

« Back to Dashboard

Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Docket   Start Trial Date Filed 2007-12-20
Court District Court, D. Delaware Date Terminated 2010-05-07
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties CURATORS OF THE UNIVERSITY OF MISSOURI; PAR PHARMACEUTICAL INC.; SANTARUS INC.
Patents 4,255,431; 4,508,905; 4,636,499; 4,738,974; 4,786,505; 4,853,230; 5,013,743; 5,045,321; 5,093,132; 5,093,342; 5,599,794; 5,629,305; 5,690,960; 5,753,265; 5,817,338; 5,840,737; 5,972,389; 6,123,962; 6,143,771; 6,147,103; 6,150,380; 6,166,213; 6,248,363; 6,489,346; 6,645,988; 6,699,885; 6,780,882
Attorneys Frederick L. Cottrell , III; Jack B. Blumenfeld; James Walter Parrett , Jr.; Steven J. Fineman
Link to Docket External link to docket
Small Molecule Drugs cited in Santarus Inc. v. Par Pharmaceutical Inc.
Biologic Drugs cited in Santarus Inc. v. Par Pharmaceutical Inc.
The biologic drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Santarus Inc. v. Par Pharmaceutical Inc. (D. Del. 2007)

Date Filed Document No. Description Snippet Link To Document
2007-12-20 1 Complaint EP 0244380 11/1987 U.S. PATENT DOCUMENTS 4,045,564 A 4,132,765 A 4,255,431 A 4,337,257 A 4,359,465 A…4,182,766 A 1/'1980 Krasso et al. 4,255,431 A 3/1981 Junggren et a!. 4,337,257 A 6/1982 Junggren et…1980 Berntsson et al. K.rasso et al. 4,255,431 A 3/1981 Junggren et al. 4,337,257 A 6/1982 Junggren et…Berntsson et al. 4,182,766 A 1/1980 Krasso et alv 4,255,431 A 3,"1981 Junggren et al. 4,337,257 A 6/1982…“885 Patent.” 9. On December 3, 2002, the PTO issued U.S. Patent No. 6,489,346 (the “‘346 Patent”), entitled External link to document
2008-02-22 10 Answer to Counterclaim counterclaims relating to U.S. Patent No. 5,840,737 (“the ‘737 patent”). Additionally, these counterclaims…admit that the ‘737 patent, ‘988 patent, ‘346 patent, ‘885 patent, and the ‘882 patent are assigned to The…Data of the ‘737 patent, ‘988 patent, ‘346 patent, ‘885 patent, and the ‘882 patent. Plaintiffs deny …admit that the ‘737 patent, ‘988 patent, ‘346 patent, ‘885 patent, and the ‘882 patent are licensed to Santarus…6,699,885 (“the ‘885 patent”); 6,489,346 (“the ‘346 patent”); 6,645,988 (“the ‘988 patent”); and 6,780,882 External link to document
2007-12-20 4 Patent/Trademark Report to Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 6,699,885; US 6,699,885; US 6,489,346; US…Curators of the University of Missouri 3 US 6,489,346 B1 12/03/2002 …University of Missouri PATENT OR DATE OF PATENT … Other Pleading PATENT OR DATE OF PATENT …REPORT ON THE TO: Director of the U.S. Patent and Trademark Office FILING External link to document
2008-01-10 6 Answer to Complaint December 3, 2002, the PTO issued U.S. Patent No. 6,489,346 (the “’346 Patent”), entitled “Substituted Benzimidazole…Paragraph 4: This is an action for patent infringement arising under the patent laws of the United States of…2004, the United States Patent and Trademark Office (the “PTO”) issued U.S. Patent No. 6,699,885, entitled…confirming that all claims of the patent “are determined to be patentable as amended.” On September 18, …’346 patent is attached as Exhibit C to the complaint and states that the face of the ’346 patent speaks External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Harvard Business School
Colorcon
McKesson
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.